Skip to main content
Neurology logoLink to Neurology
. 2016 Aug 16;87(7 Suppl 1):S4–S12. doi: 10.1212/WNL.0000000000002927

Patient-reported outcomes of pain and physical functioning in neurofibromatosis clinical trials

Pamela L Wolters 1,, Staci Martin 1, Vanessa L Merker 1, James H Tonsgard 1, Sondra E Solomon 1,, Andrea Baldwin 1, Amanda L Bergner 1, Karin Walsh 1, Heather L Thompson 1, Kathy L Gardner 1, Cynthia M Hingtgen 1, Elizabeth Schorry 1, William N Dudley 1, Barbara Franklin 1; For the REiNS International Collaboration1
PMCID: PMC5578357  PMID: 27527648

Abstract

Objective:

Tumors and other disease complications of neurofibromatosis (NF) can cause pain and negatively affect physical functioning. To document the clinical benefit of treatment in NF trials targeting these manifestations, patient-reported outcomes (PROs) assessing pain and physical functioning should be included as study endpoints. Currently, there is no consensus on the selection and use of such measures in the NF population. This article presents the recommendations of the PRO group of the Response Evaluation in Neurofibromatosis and Schwannomatosis (REiNS) International Collaboration for assessing the domains of pain and physical functioning for NF clinical trials.

Methods:

The REiNS PRO group reviewed and rated existing PRO measures assessing pain intensity, pain interference, and physical functioning using their systematic method. Final recommendations are based primarily on 4 main criteria: patient characteristics, item content, psychometric properties, and feasibility for clinical trials.

Results:

The REiNS PRO group chose the Numeric Rating Scale–11 (≥8 years) to assess pain intensity, the Pain Interference Index (6–24 years) and the Patient-Reported Outcome Measurement Information System (PROMIS) Pain Interference Scale (≥18 years) to evaluate pain interference, and the PROMIS Physical Functioning Scale to measure upper extremity function and mobility (≥5 years) for NF clinical trials.

Conclusions:

The REiNS Collaboration currently recommends these PRO measures to assess the domains of pain and physical functioning for NF clinical trials; however, further research is needed to evaluate their use in individuals with NF. A final consensus recommendation for the pain interference measure will be disseminated in a future publication based on findings from additional published research.


Neurofibromatosis 1 (NF1), neurofibromatosis 2 (NF2), and schwannomatosis (SWN) are neurogenetic disorders that share a predisposition to develop multiple nerve sheath tumors. These tumors may cause significant complications such as visual impairments, hearing loss, facial nerve palsy, airway constriction, and spinal cord compression.1 Generalized and focal orthopedic problems, including spinal and skeletal abnormalities such as scoliosis, congenital bowing, tibial pseudoarthrosis, and chest wall malformations, also may contribute to morbidity.2 Furthermore, chronic pain is common in children3,4 and adults5,6 with neurofibromatosis (NF) and may be related to tumors, physical impairments, and headaches.2,3,5,6 These complications of NF can significantly affect physical functioning, activities of daily living, and quality of life (QOL).4,6

The number of clinical trials evaluating treatments for tumors and other manifestations of NF1, NF2, and SWN has increased over the last several years. To assess clinical benefit from the patients' perspective in drug trials, investigators have begun to incorporate patient-reported outcome (PRO) measures as secondary endpoints.7 Current behavioral intervention studies focusing on reducing pain and its interference with everyday functioning use PROs as primary endpoints.8 PRO measures also can further define baseline disease characteristics7 and document effects of drug toxicities.9 Regulatory agencies in the United States and Europe recommend including PRO tools in clinical trials to systematically evaluate symptoms of interest10,11 as the data can provide complementary information about the efficacy of a new treatment.10 To support medical product approval and labeling claims in the United States, PRO tools must be qualified by the Food and Drug Administration (FDA) as a clinical outcome assessment (COA)12 and meet rigorous standards to be used as trial endpoints.11 In meetings with Response Evaluation in Neurofibromatosis and Schwannomatosis (REiNS) members, the FDA has indicated that COAs of pain and physical functioning need to be incorporated into trial design as coprimary or secondary endpoints to document clinical benefit in addition to tumor reduction for NF trials seeking drug approval.

Despite the increased interest in PROs, challenges remain in using such measures of pain and physical functioning in NF clinical trials. First, the complications of NF are heterogeneous and vary widely in prevalence and severity.1,13 Individuals often have multiple tumors and complications, making it difficult to differentiate changes in pain or functioning related to one particular tumor type or complication being treated in a clinical trial. Pain may be acute, episodic, or chronic, and vary in intensity and location. Thus, when designing an NF trial including pain PROs, researchers need to consider the frequency of evaluations, length of the response period (e.g., past 7 days), and how to track the locations of target tumors or complications in order to obtain reliable and valid assessments of pain throughout the study. Accurate recording of analgesic use also is required to help distinguish changes in pain related to tumor reduction due to the study drug from changes in pain due to analgesics.14 In addition, NF complications, such as plexiform neurofibromas3,5 and learning disabilities,15 are common in children through adults. Therefore, PRO measures used in NF trials must evaluate individuals across a wide range of ages and ability levels. To be feasible for multicenter and international studies, PRO tools need to be relatively brief, easy to administer, and available in different languages. Finally, no measures currently are validated to assess pain and physical functioning across the lifespan in NF, and there is a lack of consensus about how to assess PROs in NF clinical trials. The US FDA and European regulatory agencies have acknowledged the importance of developing a common core language and methodology for clinical trials evaluating new drugs that will permit comparisons of PROs across treatments.10

To respond to these challenges and promote consensus in the assessment of PROs in NF clinical trials, the PRO group of the REiNS International Collaboration is working to provide guidance about appropriate PRO measures and methodologies in 4 core domains (pain, physical functioning, disease-specific QOL, and general QOL) for use in NF clinical trials. The PRO group's first publication16 outlined their goals and described the systematic process they developed to review and choose PRO measures using pain intensity as an example. This article presents the current REiNS recommendations for the domains of pain and physical functioning, specifically focusing on self-report measures for ages 8 years and older and parent report questionnaires for 5 years and older.

METHODS

The group's systematic method involves gathering information from extensive literature reviews and rating existing PRO measures on 6 criteria, as previously described.16 PRO measures may be re-reviewed to consider new published data, and when scores are close, the highest-rated measures are compared directly during the same meeting. Of the 6 initial criteria, the group refined their focus to the 4 it deemed most important when making the final selection of a PRO measure17 for NF clinical trials. Thus, patient characteristics, item content, psychometric properties, and feasibility for multicenter trials were the primary criteria used to determine the recommendations in the domains of pain and physical functioning. All the PRO measures reviewed for these domains are listed in table e-1 on the Neurology® Web site at Neurology.org.

RESULTS

Pain domain.

Pain intensity recommendation.

The PRO group recommends the Numeric Rating Scale–11 (NRS-11) as a self-report measure of pain intensity (ages ≥8 years) for NF clinical trials, as described and compared in detail with other tools in our previous publication.16 On the NRS-11, respondents are asked to circle the number from 0 (no pain) to 10 (e.g., worst pain imaginable) that best represents their pain.18 The characteristics of the NRS-11 are shown in table 1.

Table 1.

Characteristics of the Numeric Rating Scale–11 (NRS-11) for the 4 main review criteria

graphic file with name NEUROLOGY2015686667TT1.jpg

Pain interference.

In the domain of pain interference, our group initially identified 7 pain interference scales to consider. Of these, 4 met basic criteria to be suitable for use in NF clinical trials and were rated using our systematic process. The top-rated measures were the Pain Interference Index (PII),19 Patient-Reported Outcome Measurement Information System Pain Interference scale (PROMIS-PI),20 and Brief Pain Inventory Pain Interference subscale.21 Our final side-by-side comparison resulted in the highest overall ratings, which were tied, for the PII and PROMIS-PI. Table 2 presents the characteristics of the PII and PROMIS-PI for each of the 4 main review criteria.

Table 2.

Characteristics of the Pain Interference Index (PII) and the Patient-Reported Outcome Measurement Information System Pain Interference scale (PROMIS-PI) for the 4 main review criteria

graphic file with name NEUROLOGY2015686667TT2.jpg

Pain Interference Index.

The PII19,22 is a 6-item scale that assesses the extent to which pain has interfered with an individual's daily activities in the past 7 days. Items are rated on a 7-point Likert scale, and the total score is the mean of the completed items. The PII is suitable for NF clinical trials because it covers a wide age range, assesses areas relevant for NF, and has parallel child and adult self-report and parent proxy forms. Importantly for use in pediatric NF trials, the child and parent forms demonstrate good reliability and validity in NF1,19 yield high correlations between parent and child scores,19 and show sensitivity to change after behavioral interventions for chronic pain in children.8 While good preliminary data exist in adults with NF1 (unpublished data) and other conditions involving pain,23 more research is needed before recommending the adult version for NF trials.

Patient-Reported Outcome Measurement Information System (PROMIS).

PROMIS was created from an NIH-sponsored initiative to develop standardized PRO measures that can be compared across patient populations and studies in a variety of health domains (http://www.nihpromis.org/). It utilizes Item Response Theory (IRT), in which each item in a large item bank is a measure of a latent trait that falls along a continuum. A small subset of these items are administered as short forms (SF) of various lengths (e.g., 8, 10, or 20 items) or as a computerized adaptive test (CAT), which selects the most relevant questions from an item bank based on a person's answers to previous questions, to produce brief and precise outcome assessments.24,25 Items are rated on a 5-point Likert scale, and the measures yield standardized T scores. PROMIS scales are appropriate for NF clinical trials because they assess relevant domains in a wide age range, have good psychometric properties, and are translated into multiple languages.

PROMIS-PI.

The PROMIS-PI20 assesses the degree to which pain has interfered with a patient's ability to complete daily activities over the past 7 days. This scale has demonstrated feasibility and validity in adults and youth with various medical conditions and chronic pain.20,26,27 The PROMIS-PI also has been shown to be responsive to changes in pain in a limited number of clinical trials with adults28 but not yet with children.29 Published studies using both the pediatric self-report and parent-proxy pain interference scales currently are scarce. The pediatric and parent forms are parallel and general parent-child agreement is moderate.30 The item content and response options of the adult form are not consistent with the child/parent forms; thus, research is needed to evaluate whether these scales can provide a reliable assessment across age ranges for longitudinal studies involving children through adults. Studies investigating the self-report and parent-proxy versions in NF, including comparisons of CAT and SF administration in children, also are required before our group can recommend the PROMIS-PI for pediatric NF trials.

Pain interference recommendation.

Since both of these pain interference tools have strengths and weaknesses for use in NF, the current REiNS recommendation is to utilize the PII in clinical trials involving children to young adults (6–24 years), the PROMIS-PI scale for adult trials (≥18 years), and when possible, both measures for trials enrolling children through adults. Since there are limited publications using the PROMIS-PI in longitudinal studies and none with the NF population to date, the PRO group recommends administering the longest PI SF available (8 items) or both the 8-item SF and CAT in NF clinical trials to compare findings. Our group will review newly published data in the future to determine the one pain interference tool most suitable for NF clinical trials.

Physical functioning domain.

In the domain of physical functioning, our group identified 6 PRO measures appropriate for consideration; 5 met basic criteria to be rated. Of these, the PROMIS Physical Functioning scale (PROMIS-PF),25 Health Assessment Questionnaire,31 and Functional Disability Inventory32 were the top-rated measures. From our final side-by-side comparison of these 3 scales, the overall rating of the PROMIS-PF for use in NF clinical trials was the highest. Table 3 presents the characteristics of the PROMIS-PF for each of the 4 main review criteria.

Table 3.

Characteristics of the Patient-Reported Outcome Measurement Information System Physical Functioning scale (PROMIS-PF) for the 4 main review criteria

graphic file with name NEUROLOGY2015686667TT3.jpg

PROMIS-PF.

The PROMIS-PF scale measures the perception of one's capability of performing specific physical activities. It includes items assessing upper extremity function, mobility (lower extremity), and, for adults, axial or head and neck function.25 The PROMIS-PF demonstrates good reliability and construct validity in adults and youth from the general population and various disease groups.2527,3335 Adult studies show that the IRT-based PROMIS-PF scales reduce floor and ceiling effects,36 are more accurate and efficient, decrease administration time, result in greater responsiveness, and require smaller study sample sizes than legacy PRO measures.36,37 Administration of the 10-item PROMIS-PF CAT to adults resulted in an efficient and precise measurement of physical functioning, which differentiated between age and disease groups.36 However, in children with cerebral palsy, the PROMIS Mobility CAT did not correlate with performance measures or differentiate known mobility groups.38 In clinical trials, the PROMIS-PF showed sensitivity to change after spine augmentation in adults28 but not after surgery in children with cerebral palsy.29

Physical functioning recommendation.

Although published studies have not used the PROMIS-PF in NF to date, the evaluation of both upper and lower extremity function as well as the range, content, and wording of the items are well-suited to assess the spectrum of complications affecting physical function in NF. Therefore, the current REiNS recommendation is to use the longest PF SF that is feasible for a particular study (e.g., 20-item SF was the most responsive in populations with physical impairments)37 or the CAT in adult studies. The CAT alone is not recommended for pediatric studies at this time since it was less accurate than the SF in children with functional limitations.38 When possible, giving both SF and CAT versions in pediatric NF studies will allow comparisons between the 2 versions to help refine these recommendations.

Recommendations for use of these measures for NF1, NF2, and SWN.

The above recommendations on pain intensity, pain interference, and physical functioning PRO measures (listed in table 4) apply to clinical trials enrolling patients with NF1, NF2, or SWN. Each measure was evaluated for its ability to capture relevant changes in disease status regardless of the particular syndrome being studied (e.g., adequately measuring pain interference from plexiform neurofibromas in NF1 or from generalized chronic pain in SWN). Since the NRS-11, PII, PROMIS-PI, and PROMIS-PF assess generalized constructs rather than disease-specific manifestations of pain and disability, they are suited for a range of clinical trials in NF1, NF2, and SWN. However, the patient population and objectives of a particular clinical trial will dictate which of these PRO measures are most appropriate and whether additional measures may be needed to capture the full range of relevant PROs adequately. For example, a targeted measure on swallowing or breathing may be warranted for studies on plexiform tumors causing airway compression in NF1. Similarly, in trials for symptomatic vestibular schwannomas in NF2, targeted questionnaires on the effect of balance problems on physical activities or the effect of hearing decline on communicative ability may be warranted.

Table 4.

Response Evaluation in Neurofibromatosis and Schwannomatosis (REiNS) patient-reported outcome recommendations for the pain and physical functioning domains in neurofibromatosis clinical trials

graphic file with name NEUROLOGY2015686667TT4.jpg

DISCUSSION

PROs assessing pain and physical functioning are critical for documenting the clinical efficacy of treatments targeting manifestations of NF1, NF2, and SWN. The REiNS International Collaboration provides consensus recommendations regarding PROs to the NF research community based on extensive review of existing tools in these domains.

To assess pain intensity, the REiNS International Collaboration recommends the NRS-11 as a brief, reliable, and valid self-report scale to assess pain intensity for ages 8 years and older, as previously described.16 However, for NF clinical trials targeting tumor reduction, research needs to explore modifications for assessing tumor-specific pain and indicating the location of the tumor pain being rated throughout a trial.

To assess pain interference, the current REiNS recommendation includes 2 measures until additional data are published to determine the most appropriate one for use in NF clinical trials across all age groups. At this time, the REiNS group recommends the PII for pediatric studies and the PROMIS-PI for adult trials. Both measures are recommended for NF studies including children and adults so the data can be compared. The PII is valid in children with NF1 and their parents19; however, there currently are no published data in adults with NF1. The PROMIS-PI20 is an IRT-based measure that has been used in several published studies with adults, has excellent feasibility, and has robust psychometric properties. However, additional research is needed to examine the use of the PROMIS-PI in children and parents, individuals with NF, and CAT in longitudinal studies.

In the domain of physical functioning, the REiNS Collaboration recommends the PROMIS-PF scale.25 Although relatively new, the PROMIS-PF was deemed the most appropriate for NF clinical trials because it evaluates both upper and lower extremity functioning, consisting of a range of motor functions and daily living activities that are important to assess in NF. This scale should provide an efficient and precise PRO assessment of physical functioning and require smaller sample sizes,37 which is important for clinical trials of rare diseases. However, CAT administration was not as accurate as the SF in children with functional limitations so both administration options need to be examined in the NF population. Additional information also is needed on the use of the pediatric scales over time.27

Limitations.

The continued work of the REiNS Collaboration and the broader scientific community will be important in addressing the current limitations associated with these recommendations. First is the challenge of whether these PRO tools accurately assess the specific types of pain and physical functions being evaluated in clinical trials for individuals with NF when multiple factors may contribute to their pain experience or impact their daily functioning. Another issue is the lack of data in NF1, NF2, and SWN and whether the psychometric properties of the scale in these conditions will be consistent with those documented in the general population. Additionally, no PRO tools to date have shown the ability to measure pain and physical functioning adequately for all ages. In particular, researchers need to address the evaluation of these domains in children under 8 years old since NF trials are enrolling these younger participants. This challenge is reflected in our recommendation of 2 pain interference scales, as currently there are insufficient published data for establishing the validity of either measure in children and adults with NF. Identifying the most appropriate methods to assess children with significant cognitive impairments also needs to be addressed. Our group will update our recommendations in these specific areas in future publications.

To address the limitations noted above, PRO group members are using these recommended pain and physical functioning measures in descriptive studies and clinical trials with a wide age range of individuals who have all types of NF. Several of these PROs have been accepted into the FDA's Drug Development Tool COA Qualification Program12 and are being further studied with both qualitative and quantitative research methods11 to examine possible modifications and their use as NF clinical trial endpoints. The PRO working group also plans to form a subgroup that will focus on identifying measures to assess young children and individuals with significant cognitive impairments. Finally, researchers need to investigate the use of new methodologies in NF clinical trials to improve PRO data, such as using electronic administration to increase the accuracy and speed of data collection.39

The REiNS PRO group is working to identify PRO measures that can be used consistently as endpoints across trials to assess clinical benefit of treatments to reduce tumors or other disease manifestations in individuals with NF1, NF2, and SWN. The REiNS recommendations for PROs in the domains of pain and physical functioning are presented with the understanding that further evaluation of the measures is needed in the NF population. Our group encourages researchers to use these PRO measures in upcoming NF studies. Final consensus recommendations regarding the one specific pain interference measure and format of the PROMIS-PF scales to use in NF clinical trials will be disseminated in a future publication based on results of additional published research.

ACKNOWLEDGMENT

The authors thank Ana-Maria Vranceanu, PhD, Department of Psychiatry, Harvard Medical School, a new member of the REiNS PRO working group, for participation in selected conference calls to discuss reviewed PRO measures.

GLOSSARY

CAT

computerized adaptive test

COA

clinical outcome assessment

FDA

Food and Drug Administration

IRT

Item Response Theory

NF

neurofibromatosis

NF1

neurofibromatosis 1

NF2

neurofibromatosis 2

NRS-11

Numeric Rating Scale–11

PII

Pain Interference Index

PRO

patient-reported outcome

PROMIS

Patient-Reported Outcome Measurement Information System

PROMIS-PF

Patient-Reported Outcome Measurement Information System Physical Functioning scale

PROMIS-PI

Patient-Reported Outcome Measurement Information System Pain Interference scale

QOL

quality of life

REiNS

Response Evaluation in Neurofibromatosis and Schwannomatosis

SF

short forms

SWN

schwannomatosis

Footnotes

Supplemental data at Neurology.org

Contributor Information

Collaborators: REiNS International Collaboration Members 2016, Shivani Ahlawat, Srivandana Akshintala, Jeffrey Allen, Simone Ardern-Holmes, Robert Avery, Amedeo Azizi, Dusica Babovic-Vuksanovic, Annette Bakker, Andrea Baldwin, Fred Barker, Amanda Bergner, Chetan Bettegowda, Sucharita Bhaumik, Larissa Bilaniuk, Kim Bischoff, Jaishri Blakely, Diana Bradford, Miriam Bredella, Wenli Cai, John Carino, Avneesh Chabra, Patricia Ciavarelli, Wade Clapp, Stephen Connor, Albert Cornelius, Tambra Dahlheimer, Stephanie Davis, Peter de Blank, Vidya Dhote, Joni Doherty, Eva Dombi, William Dudley, Rachel Ershler, D. Gareth Evans, Laura Fayad, Cristina Fernandez-Valle, Rosalie Ferner, Michael Fisher, Barbara Franklin, Giulia Fulci, Tracy Galloway, Kathy Gardner, Richard Gedrich, Marco Giovannini, Amy Goldstein, Anne Goodwin, Stephane Goutagny, David Gutmann, Theresa Hadlock, Chris Halpin, C. Oliver Hanemann, Kristina Hardy, Gordon Harris, Desiree Headley, Gena Heidary, Jonathan Heller, Cynthia Hingtgen, Trent Hummel, Susan Huson, Michael Jacobs, Jennifer Janusz, Diego Jaramillo, Justin Jordan, Allen Julian, Michel Kalamarides, Matthias Karajannis, Bonnie Klein-Tasman, Pamela Knight, Bruce Korf, Shannon Langmead, Theresa LaVallee, Fawn Leigh, Donita Lightner, Carol Lin, Robert Listernick, Grant Liu, Mevo Marco, Carole Marcus, Gabriella Mariani, Staci Martin, Victor Mautner, Vanessa Merker, Michael Ferguson, Chris Moertel, Jill Morris, Katrina Morris, Kathryn North, Fabio Nunes, Roger Packer, Laura Papi, Allyson Parry, Neha Patel, Jonathan Payne, Karen Peluso, Sebastian Perreault, Scott Plotkin, Tina Poussaint, Nancy Ratner, Karlyne Reilly, Vincent Riccardi, Kent Robertson, Claas Rohl, Deborah Rukin Gold, La Rosa Salvatore, Laura Schaffner Gray, Elizabeth Schorry, Claire Semerjian, Monica Sheridan, Chie-Schin Shih, Carolyn Sidor, William Slattery, III, Miriam Smith, Kathy Sommer, Marigo Stathis, Matt Steensma, Anat Stemmer-Rachamimov, David Stevenson, Kari Struemph, Lara Sullivan, Mary Anne Tamula, Mary Thomas, Heather Thompson, James Tonsgard, Nicole Ullrich, Sharad Verma, David Viskochil, Ana-Maria Vranceanu, Ute Wahllander, Karin Walsh, Bradley Welling, Ralph Wenzel, Trish Whitcomb, Brigitte Widemann, Victoria Williams, David Wolf, Pamela Wolters, and Kaleb Yohay

AUTHOR CONTRIBUTIONS

Pamela Wolters: design and conceptualization of the study, collection and interpretation of the data, drafting and revising the manuscript. Staci Martin: design and conceptualization of the study, collection and interpretation of the data, drafting and revising the manuscript. Vanessa Merker: study concept, collection and interpretation of the data, drafting and revising the manuscript. Jim Tonsgard: study concept, collection and interpretation of the data, drafting and revising the manuscript. Sondra Solomon: study concept, collection and interpretation of the data, drafting and revising the manuscript. Andrea Baldwin: study concept, collection and interpretation of the data, drafting and revising the manuscript. Amanda Bergner: study concept, collection and interpretation of the data, drafting and revising the manuscript. Karin Walsh: study concept, collection and interpretation of the data, drafting and revising the manuscript. Heather Thompson: study concept, collection and interpretation of the data, drafting and revising the manuscript. Kathy Gardner: study concept, collection and interpretation of the data, revising the manuscript. Cynthia Hingtgen: study concept, collection and interpretation of the data, revising the manuscript. Elizabeth Schorry: study concept, collection and interpretation of the data, revising the manuscript. William Dudley: study concept, collection and interpretation of the data, revising the manuscript. Barbara Franklin: study concept, collection and interpretation of the data, revising the manuscript.

STUDY FUNDING

This research is supported by the Intramural Research Program of the National Institutes of Health, National Cancer Institute.

DISCLOSURE

P. Wolters received funding from the Neurofibromatosis Therapeutics Acceleration Program and holds stock in Bristol-Meyers-Squibb. S. Martin received funding from the Neurofibromatosis Therapeutics Acceleration Program. She also received funded travel for speaking engagements from the University of Chicago and the Children's Tumor Foundation. V. Merker reports no disclosures relevant to the manuscript. J. Tonsgard receives funding from the Department of Defense Army Research Command as part of the NF Consortium and from Midwest NF, Inc. S. Solomon is deceased; she reported no disclosures relevant to the manuscript. A. Baldwin and A. Bergner report no disclosures relevant to the manuscript. K. Walsh received funding from the Children's Tumor Foundation, the Department of Defense, and the Gilbert Neurofibromatosis Institute. H. Thompson and K. Gardner report no disclosures relevant to the manuscript. C. Hingtgen holds stock in Merck. B. Schorry receives funding from the Department of Defense as a site PI for the NF Consortium and also as a coinvestigator for a clinical trial of vitamin D for adults with NF1. W. Dudley and B. Franklin report no disclosures relevant to the manuscript. Go to Neurology.org for full disclosures.

REFERENCES

  • 1.Korf BR. Neurofibromatosis. Handb Clin Neurol 2013;111:333–340. [DOI] [PubMed] [Google Scholar]
  • 2.Elefteriou F, Kolanczyk M, Schindeler A, et al. . Skeletal abnormalities in neurofibromatosis type 1: approaches to therapeutic options. Am J Med Genet A 2009;149A:2327–2338. [DOI] [PubMed] [Google Scholar]
  • 3.Nguyen R, Kluwe L, Fuensterer C, Kentsch M, Friedrich RE, Mautner VF. Plexiform neurofibromas in children with neurofibromatosis type 1: frequency and associated clinical deficits. J Pediatr 2011;159:652–655. [DOI] [PubMed] [Google Scholar]
  • 4.Wolters PL, Burns KM, Martin S, et al. . Pain interference in youth with neurofibromatosis type 1 and plexiform neurofibromas and relation to disease severity, social-emotional functioning, and quality of life. Am J Med Genet A 2015;167A:2103–2113. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Creange A, Zeller J, Rostaing-Rigattieri S, et al. . Neurological complications of neurofibromatosis type 1 in adulthood. Brain 1999;122:473–481. [DOI] [PubMed] [Google Scholar]
  • 6.Merker VL, Bredella MA, Cai W, et al. . Relationship between whole-body tumor burden, clinical phenotype, and quality of life in patients with neurofibromatosis. Am J Med Genet A 2014;164A:1431–1437. [DOI] [PubMed] [Google Scholar]
  • 7.Widemann BC, Babovic-Vuksanovic D, Dombi E, et al. . Phase II trial of pirfenidone in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas. Pediatr Blood Cancer 2014;61:1598–1602. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Martin S, Wolters P, Toledo-Tamula MA, et al. . Acceptance and commitment therapy in youth with neurofibromatosis type 1 (NF1) and chronic pain and their parents: a pilot study of feasibility and preliminary efficacy. Am J Med Genet 2016;170:1462–1470. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Kim A, Dombi E, Tepas K, et al. . Phase I trial and pharmacokinetic study of sorafenib in children with neurofibromatosis type I and plexiform neurofibromas. Pediatr Blood Cancer 2013;60:396–401. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Acquadro C, Berzon R, Dubois D, et al. . Incorporating the patient's perspective into drug development and communication: an ad hoc task force report of the Patient-Reported Outcomes (PRO) Harmonization Group meeting at the Food and Drug Administration, February 16, 2001. Value Health 2003;6:522–531. [DOI] [PubMed] [Google Scholar]
  • 11.US Department of Health and Human Services FDA Center for Drug Evaluation and Research; US Department of Health and Human Services FDA Center for Biologics Evaluation and Research; US Department of Health and Human Services FDA Center for Devices and Radiological Health. Guidance for Industry: patient-reported outcome measures: use in medical product development to support labeling claims. Health Qual Life Outcomes 2006;4:79. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.US Food and Drug Administration. Clinical Outcome Assessment Compendium. Mary Land: US Food and Drug Administration; 2016. [Google Scholar]
  • 13.Hoa M, Slattery WH III. Neurofibromatosis 2. Otolaryngol Clin North Am 2012;45:315–332. [DOI] [PubMed] [Google Scholar]
  • 14.Cleeland CS, O'Mara A, Zagari M, Baas C. Integrating pain metrics into oncology clinical trials. Clin Cancer Res 2011;17:6646–6650. [DOI] [PubMed] [Google Scholar]
  • 15.Hyman SL, Shores A, North KN. The nature and frequency of cognitive deficits in children with neurofibromatosis type 1. Neurology 2005;65:1037–1044. [DOI] [PubMed] [Google Scholar]
  • 16.Wolters PL, Martin S, Merker VL, et al. . Patient-reported outcomes in neurofibromatosis and schwannomatosis clinical trials. Neurology 2013;81:S6–S14. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.McClimans LM, Browne J. Choosing a patient-reported outcome measure. Theor Med Bioeth 2011;32:47–60. [DOI] [PubMed] [Google Scholar]
  • 18.Miro J, Castarlenas E, Huguet A. Evidence for the use of a numerical rating scale to assess the intensity of pediatric pain. Eur J Pain 2009;13:1089–1095. [DOI] [PubMed] [Google Scholar]
  • 19.Martin S, Nelson Schmitt S, Wolters PL, et al. . Development and validation of the English pain interference index and pain interference index-parent report. Pain Med 2015;16:367–373. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Amtmann D, Cook KF, Jensen MP, et al. . Development of a PROMIS item bank to measure pain interference. Pain 2010;150:173–182. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Cleeland CS, Ryan KM. Pain assessment: global use of the brief pain inventory. Ann Acad Med Singapore 1994;23:129–138. [PubMed] [Google Scholar]
  • 22.Holmstrom L, Kemani MK, Kanstrup M, Wicksell RK. Evaluating the statistical properties of the pain interference index in children and adolescents with chronic pain. J Dev Behav Pediatr 2015;36:450–454. [DOI] [PubMed] [Google Scholar]
  • 23.Kemani M, Zetterqvist V, Kanstrup M, Wicksell R, Holmström L. A validation of the pain interference index in adults with longstanding pain. Acta Anaesthesiol Scand 2016;60:250–258. [DOI] [PubMed] [Google Scholar]
  • 24.Bevans M, Ross A, Cella D. Patient-Reported Outcomes Measurement Information System (PROMIS): efficient, standardized tools to measure self-reported health and quality of life. Nurs Outlook 2014;62:339–345. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Rose M, Bjorner JB, Becker J, Fries JF, Ware JE. Evaluation of a preliminary physical function item bank supported the expected advantages of the Patient-Reported Outcomes Measurement Information System (PROMIS). J Clin Epidemiol 2008;61:17–33. [DOI] [PubMed] [Google Scholar]
  • 26.Broderick JE, Schneider S, Junghaenel DU, Schwartz JE, Stone AA. Validity and reliability of patient-reported outcomes measurement information system instruments in osteoarthritis. Arthritis Care Res 2013;65:1625–1633. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.DeWalt DA, Gross HE, Gipson DS, et al. . PROMIS pediatric self-report scales distinguish subgroups of children within and across six common pediatric chronic health conditions. Qual Life Res 2015;24:2195–2208. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Shahgholi L, Yost KJ, Kallmes DF. Correlation of the National Institutes of Health patient reported outcomes measurement information system scales and standard pain and functional outcomes in spine augmentation. AJNR Am J Neuroradiol 2012;33:2186–2190. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Mulcahey MJ, Haley SM, Slavin MD, et al. . Ability of PROMIS pediatric measures to detect change in children with cerebral palsy undergoing musculoskeletal surgery. J Pediatr Orthop Epub 2015 Jun 5. [DOI] [PMC free article] [PubMed]
  • 30.Varni JW, Thissen D, Stucky BD, et al. . PROMIS(R) Parent Proxy Report Scales: an item response theory analysis of the parent proxy report item banks. Qual Life Res 2012;21:1223–1240. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Bruce B, Fries JF. The Health Assessment Questionnaire (HAQ). Clin Exp Rheumatol 2005;23:S14–S18. [PubMed] [Google Scholar]
  • 32.Walker LS, Greene JW. The Functional Disability Inventory: measuring a neglected dimension of child health status. J Pediatr Psychol 1991;16:39–58. [DOI] [PubMed] [Google Scholar]
  • 33.DeWitt EM, Stucky BD, Thissen D, et al. . Construction of the eight-item patient-reported outcomes measurement information system pediatric physical function scales: built using item response theory. J Clin Epidemiol 2011;64:794–804. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Jensen RE, Potosky AL, Reeve BB, et al. . Validation of the PROMIS physical function measures in a diverse US population-based cohort of cancer patients. Qual Life Res 2015;24:2333–2344. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Varni JW, Magnus B, Stucky BD, et al. . Psychometric properties of the PROMIS (R) pediatric scales: precision, stability, and comparison of different scoring and administration options. Qual Life Res 2014;23:1233–1243. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Rose M, Bjorner JB, Gandek B, Bruce B, Fries JF, Ware JE Jr. The PROMIS Physical Function item bank was calibrated to a standardized metric and shown to improve measurement efficiency. J Clin Epidemiol 2014;67:516–526. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Fries JF, Krishnan E, Rose M, Lingala B, Bruce B. Improved responsiveness and reduced sample size requirements of PROMIS physical function scales with item response theory. Arthritis Res Ther 2011;13:R147. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Kratz AL, Slavin MD, Mulcahey MJ, Jette AM, Tulsky DS, Haley SM. An examination of the PROMIS(R) pediatric instruments to assess mobility in children with cerebral palsy. Qual Life Res 2013;22:2865–2876. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Palermo TM, Valenzuela D, Stork PP. A randomized trial of electronic versus paper pain diaries in children: impact on compliance, accuracy, and acceptability. Pain 2004;107:213–219. [DOI] [PubMed] [Google Scholar]
  • 40.von Baeyer CL. Numerical rating scale for self-report of pain intensity in children and adolescents: recent progress and further questions. Eur J Pain 2009;13:1005–1007. [DOI] [PubMed] [Google Scholar]
  • 41.Castarlenas E, Miro J, Sanchez-Rodriguez E. Is the verbal numerical rating scale a valid tool for assessing pain intensity in children below 8 years of age? J Pain 2013;14:297–304. [DOI] [PubMed] [Google Scholar]
  • 42.Bailey B, Daoust R, Doyon-Trottier E, Dauphin-Pierre S, Gravel J. Validation and properties of the verbal numeric scale in children with acute pain. Pain 2010;149:216–221. [DOI] [PubMed] [Google Scholar]
  • 43.Good M, Stiller C, Zauszniewski JA, Anderson GC, Stanton-Hicks M, Grass JA. Sensation and distress of pain scales: reliability, validity, and sensitivity. J Nurs Meas 2001;9:219–238. [PubMed] [Google Scholar]
  • 44.Varni JW, Thissen D, Stucky BD, et al. . Item-level informant discrepancies between children and their parents on the PROMIS pediatric scales. Qual Life Res 2015;24:1921–1937. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Neurology are provided here courtesy of American Academy of Neurology

RESOURCES